Open Medicine (Feb 2024)
METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients
- Tan Quandan,
- Yang Le,
- Yuan Shanshan,
- Zheng Danni,
- Lin Yapeng,
- Chen Kejie,
- He Ying,
- Chen Shuntian,
- Hao Junli,
- Dai Jin,
- He Song,
- Mao Fengkai,
- Leng Xinyi,
- Jiang Haisong,
- Yang Jie
Affiliations
- Tan Quandan
- Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Yang Le
- Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Yuan Shanshan
- Department of Critical Care Medicine, The General Hospital of Western Theater Command, Chengdu, China
- Zheng Danni
- Biomedical Informatics and Digital Health, School of Medical Sciences, University of Sydney, Sydney, Australia
- Lin Yapeng
- Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Chen Kejie
- School of Public Health, Chengdu Medical College, Chengdu, China
- He Ying
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Chen Shuntian
- School of Biomedical Sciences and Technology, Chengdu Medical College, Chengdu, China
- Hao Junli
- School of Biomedical Sciences and Technology, Chengdu Medical College, Chengdu, China
- Dai Jin
- School of Biomedical Sciences and Technology, Chengdu Medical College, Chengdu, China
- He Song
- Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Mao Fengkai
- Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
- Leng Xinyi
- Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
- Jiang Haisong
- Department of Neurology, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Yang Jie
- Department of Neurology, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- DOI
- https://doi.org/10.1515/med-2024-0899
- Journal volume & issue
-
Vol. 19,
no. 1
pp. S6 – 16
Abstract
N6-methyladenosine (m6A) is the most frequently occurring interior modification in eukaryotic messenger RNA (mRNA), and abnormal mRNA modifications can affect many biological processes. However, m6A’s effect on the metabolism of antiplatelet drugs for the prevention of ischemic stroke (IS) remains largely unclear.
Keywords
